甲磺酸奥西替尼对NSCLC小鼠血清CA125、CEA及VEGF表达的影响研究  

Effect of osimertinibmesylate on the expression of serum CA125,CEA and VEGF in NSCLC mice

作　　者：梁敏[1] 王强[2] LIANG Min;WANG Qiang(Department of Thoracic Surgery,the Affiliated Hospital of North Sichuan Medical College,Nanchong,Sichuan　637000,China)

机构地区：[1]川北医学院附属医院胸心外科,四川南充637000 [2]川北医学院附属医院检验科,四川南充637000

出　　处：《临床肺科杂志》2018年第2期284-287,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的研究甲磺酸奥西替尼对NSCLC小鼠血清CA125、CEA及VEGF表达及生存时间的影响。方法将SCID小鼠随机分为4组:正常组、模型组及低高2个剂量实验组(甲磺酸奥西替尼0.5,1.5mg·Kg-1),每组30只,将人非小细胞肺癌H460SM细胞(EGFR-TKIs耐药)接种于模型组及低高剂量实验组SCID小鼠左肺内。饲养21天后,低高剂量实验组腹腔注射给药;正常组及模型组给予注射同等剂量蒸馏水,给药后第7天,取小鼠静脉血。采用电化学发光分析法测定CA125、CEA;采用ELISA检测法测定VEGF;并观察期生存时间。结果给药后,正常组小鼠血清CA125、CEA、VEGF分别为(5.60±0.01)U/mL、(2.89±1.38)ng/mL、(1.85±3.98)pg/mL,模型组大鼠血清CA125、CEA、VEGF分别为(7.78±0.56)U/mL、(26.79±5.56)ng/mL、(42.05±5.56)pg/mL,低剂量实验组大鼠血清CA125、CEA、VEGF分别为(7.35±0.53)U/mL、(12.78±5.53)ng/mL、(15.35±6.53)pg/mL,高剂量实验组大鼠血清CA125、CEA、VEGF分别为(5.86±0.75)U/mL、(5.86±2.75)ng/mL、(7.86±3.75)pg/mL。正常组小鼠血清CA125、CEA、VEGF均低于其他组(P<0.05),而模型组大鼠血清CA125、CEA、VEGF显著高于其他组(P<0.05),高剂量实验组CA125、CEA、VEGF指标显著低于低剂量实验组(P<0.05)。模型组、低剂量实验组、高剂量实验组小鼠的平均生存时间分别为(31.01±2.91)d、(35.05±3.73)d、(44.72±2.95)d,正常组小鼠的平均生存时间最长,低剂量实验组小鼠的平均生存时间明显高于模型组(P<0.05),低于高剂量实验组(P<0.05)。结论甲磺酸奥西替尼能够降低小鼠血清CA125、CEA、VEGF水平,具有良好的应用价值,以期应用于临床提高NSCLC治疗效果。Objective To study the effect of of osimertinibmesylate on the expression of serum CA125,CEA and VEGF in NSCLC mice.Methods The SCID mice were randomly divided into 4 groups:the normal group,the model group,and the low and high dose experimental group(imatinib mesylate Oce 0.5,1.5mg,Kg-1),30 rats in each group.The human non-small cell lung cancer H460SM cells(EGFR-TKIs resistant)were inoculated in the model group and the low dose experimental group SCID mice left the lung.After 21 days,the low and high dose groups were injected intraperitoneally.The normal group and the model group were given the same dose of distilled water,and the venous blood of the mice was taken 7 days after the administration.CA125 and CEA were determined by electrochemiluminescence assay,and VEGF was detected by ELISA.Results After administration,the levels of serum CA125,CEA and VEGF were respectively(5.60±0.01)U/mL,(2.89±1.38)ng/mL,(1.85±3.98)pg/mL in the normal group,(7.78±0.56)U/mL,(26.79±5.56)ng/mL,and(42.05±5.56)pg/mL in the model group,(7.35±0.53)U·mL,(12.78±5.53)ng/mL and(15.35±6.53)pg/mL in the low dose experimental group,and(5.86±0.75)U/mL,(5.86±2.75)ng/mL and(7.86±3.75)pg/mL in the high dose experimental group.The levels of serum CA125,CEA and VEGF were lower in the normal group than in the rest three groups(P<0.05),followed by the model group,the high dose group and the low dose group(P<0.05).The average survival time of the model group,the low dose experimental group and the high dose experimental group were(31.01±2.91)d,(35.05±3.73)d,and(44.72±2.95)d respectively,which was the longest in the normal group was the longest,followed by the high dose group,the low-dose group and the model group(P<0.05).Conclusion Osimertinibmesylate can reduce the fractional serum levels of CA125,CEA and VEGF.It has good application value,so as to improve the effect of NSCLC treatment.

关 键 词：甲磺酸奥西替尼 糖类抗原125(CA125) 癌胚抗原(CEA) 血管内皮生长因子 

分 类 号：R734.2[医药卫生—肿瘤]